DGAP-News: msg life ag: msg life publishes its report for

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Aug 17, 2016 at 3:30 AM

DGAP-News: msg life ag: msg life publishes its report for the first half-year

DGAP-News: msg life ag / Key word(s): Half Year Results msg life ag: msg life publishes its report for the first half-year 17.08.2016 / 09:18 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- msg life publishes its report for the first half-year (Leinfelden-Echterdingen, 17 August 2016) - msg life ag (ISIN DE0005130108) published its consolidated financial report for the first half-year of 2016 today. According to the report, both the aggregate turnover of 57.1 million euros (30 June 2015: 52.2 million euros) and earnings before interest, taxes, depreciation and amortisation (EBITDA) of 2.8 million euros (30 June 2015: 2.9 million euros) were on target for the year as at 30 June 2016. EBITDA comprises expenses of 0.8 million euros from the reported settlement in connection with the former stake in B+S Banksysteme Aktiengesellschaft. With consideration for factors such as tax expenditure of 1.8 million euros, as at 30 June 2016 msg life generated net income of 0.1 million euros for the period (30 June 2015: 1.2 million euros) and therefore break- even earnings per share (30 June 2015: 0.03 euros). The positive cash flows from operating activities totalled 0.8 million euros (30 June 2015: 1.5 million euros). Equity as at 30 June 2016 totalled 46.2 million euros, remaining at almost the same level as at 31 December 2015. The equity ratio was 54.3 per cent as at 30 June 2016 (31 December 2015: 56.8 per cent). At the end of the first half of 2016, msg life employed a total of 882 members of staff (30 June 2015: 859 employees). In addition to several new contracts, msg life registered further stable business with existing customers in the reporting period, a fact which attests to their level of confidence in the company. In light of the generally promising sales pipeline, the company expects further sales successes in the second half of the year. In the 2016 financial year, msg life expects earnings before interest, taxes, depreciation of property, plant and equipment and amortisation of intangible assets (EBITDA) of between 10.0 and 12.0 million euros and aggregate turnover of between 110.0 and 112.0 million euros. About msg life As part of the independent, internationally active msg Group, msg life ag and its Group companies are among the leading software and consulting companies for the European insurance sector and concentrate primarily on life insurance companies and pension fund institutions. Their products and services range from standard software through consulting services to the assumption of responsibility for IT operations (cloud solutions). The msg life Group has its head office in Leinfelden-Echterdingen and offices in Munich, Aachen, Düsseldorf, Hamburg and Cologne, plus subsidiaries in the Netherlands, Austria, Switzerland, Slovakia, Slovenia, Poland, Portugal and the USA. It currently employs a workforce of around 900. Contact msg life ag Corporate Communications Frank Fahrner Humboldtstrasse 35 70771 Leinfelden-Echterdingen Tel.: +49 (0)711 94958-0 Email: presse@msg-life.com Internet: www.msg-life.com --------------------------------------------------------------------------- 17.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: msg life ag Humboldtstraße 35 70771 Leinfelden-Echterdingen Germany Phone: +49 (0)711 94958-0 Fax: +49 (0)711 94958-49 E-mail: investor.relations@msg-life.com Internet: www.msg-life.com ISIN: DE0005130108 WKN: 513010 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 493433 17.08.2016

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

EFICYENT Ventures to Connect at Singapore FinTech Fest

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...